Home Beckman Coulter Unveils Two New Locally-Manufactured Products, Advancing Its China Localization Strategy

Beckman Coulter Unveils Two New Locally-Manufactured Products, Advancing Its China Localization Strategy

Mar 16, 2024 20:40 CST Updated 20:40

 

From March 16 to 18, 2024, the 21st China Association of Clinical Laboratory Practice (CACLP) Expo was held in Chongqing. Danaher, a global innovator in science and technology, made its debut as a group, showcasing 14 operating companies including Beckman Coulter. With a total exhibition area of 450 square meters, the company presented a more diverse and rich product portfolio, along with cutting-edge and flexible solution combinations, comprehensively demonstrating the group’s local innovations and breakthroughs in disease diagnosis and treatment.

 

At this exhibition, Beckman Coulter unveiled a “new” presence through three dimensions—innovative exhibition models, premier product launches, and strategic advancements—showcasing robust localization achievements that underscore its commitment to further meeting the needs of local customers.

 

图片 1.png

Danaher Booth

 

New Exhibition Model Highlights Local Innovation Breakthroughs


Chen Xiaosui, President of Danaher’s Medical Diagnostics Platform in China and Global Vice President & General Manager for Greater China at Beckman Coulter Diagnostics, stated in his opening remarks: “As Danaher celebrates its 40th anniversary this year, we are making our debut with a ‘new look,’ presenting 14 operating companies under the group umbrella for the first time. The aggregating effect of CACLP has allowed us to feel the surging vitality unleashed by China’s IVD industry. We will continue to leverage the momentum of CACLP, joining hands with partners from industry, academia, research, and clinical practice to promote resource sharing, industrial integration, and mutual innovation advancement with an innovative and open spirit, collectively driving the in vitro diagnostics industry toward higher-quality development.”

  图片 2.png

Chen Xiaosui, President of Danaher China Medical Diagnostics Platform, and Global Vice President & General Manager, China Region, Beckman Coulter Clinical Diagnostics, Delivered the Opening Remarks

 

Launch of New Products to Meet Broad Market Demand


In recent years, Beckman Coulter has continuously deepened its local manufacturing capabilities in China through sustained investment in production and R&D, successively launching a series of domestically produced new products. The prominent launch of the DxA 5000 Fit automated sample processing system and the DxC 700 AU automated chemistry analyzer at CACLP marks a significant milestone in Beckman Coulter’s commitment to serving the diverse needs of customers across the broad market more effectively and efficiently. It also exemplifies the company’s further advancement in localization in China. Looking ahead, Beckman Coulter will continue to empower laboratory operational excellence and support the development of laboratory medicine in China.

 

图片 3.png DxA 5000 Fit and DxC 700 AU Launch Ceremony

 

New Strategic Progress, Pioneering a New Era of Localization


To better integrate into China’s healthcare market, where demand continues to grow, Danaher has upgraded its local strategy by introducing the “Dual Innovation Acceleration Engine.” This initiative focuses on fostering innovation within healthcare institutions and empowering the translation of research outcomes in universities and industrial parks. It deeply connects government bodies, hospitals, universities, research institutions, enterprises, and capital investors to participate in the commercialization of innovative achievements in China. Guided by this strategy, Beckman Coulter will accelerate and intensify its localization efforts, continuously expanding the boundaries of localization to spawn new models and drive new momentum. This will further develop local “new quality productive forces” and enable a faster response to the demands of the Chinese market.

 

Beckman Coulter Achieved a Perfect Start to 2024 at This Year’s CACLP. Moving forward, Beckman Coulter will press on with resilience. In this pivotal year as Danaher’s “Create China” initiative enters its 2.0 phase, the company will remain customer- and patient-centric, continue to strengthen its long-term commitment to the Chinese market, write new chapters of excellence, and co-create a healthier future!